secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124653
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025
--------------------------------------------------------------------------------

- Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.
- Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.
- Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).
- Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.
- Inducement grants of options to purchase 132,350 shares to three new employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/0000950170-24-124653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/cogt-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer